Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Retained Earnings (2019 - 2025)

Historic Retained Earnings for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$3.6 billion.

  • BridgeBio Pharma's Retained Earnings fell 2815.46% to -$3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 billion, marking a year-over-year decrease of 2815.46%. This contributed to the annual value of -$3.1 billion for FY2024, which is 2092.41% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Retained Earnings is -$3.6 billion, which was down 2815.46% from -$3.4 billion recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Retained Earnings ranged from a high of -$1.0 billion in Q1 2021 and a low of -$3.6 billion during Q3 2025
  • Moreover, its 5-year median value for Retained Earnings was -$2.2 billion (2023), whereas its average is -$2.2 billion.
  • In the last 5 years, BridgeBio Pharma's Retained Earnings plummeted by 9506.36% in 2021 and then tumbled by 1834.43% in 2024.
  • Quarter analysis of 5 years shows BridgeBio Pharma's Retained Earnings stood at -$1.4 billion in 2021, then crashed by 33.49% to -$1.9 billion in 2022, then crashed by 33.49% to -$2.6 billion in 2023, then dropped by 20.92% to -$3.1 billion in 2024, then decreased by 17.18% to -$3.6 billion in 2025.
  • Its last three reported values are -$3.6 billion in Q3 2025, -$3.4 billion for Q2 2025, and -$3.3 billion during Q1 2025.